We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00496847
First Posted: July 4, 2007
Last Update Posted: December 16, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Virchow Group
  Purpose
PERIOGEN, containing rhPDGF and -beta-TCP, promotes gingival healing and corrects periodontal defects. This study will test the safety and efficacy of PERIOGEN in the treatment of periodontal disease

Condition Intervention Phase
Intrabony Periodontal Defect Drug: PERIOGEN Drug: Beta TCP alone Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study on the Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect - A Double-blind, Controlled, Randomised,Parallel,Multi-centre Study

Further study details as provided by Virchow Group:

Primary Outcome Measures:
  • 1.Area under curve (AUC) of clinical attachment level (CAL) gain (0-24 weeks) 2.Extent of linear bone growth (LBG) and percentage of bone fill (%BF) at 6 months. [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • 1.Changes in CAL gain, probing depth and gingival recession at 3 and 6 months. 2.Incidence of adverse events. [ Time Frame: 3 and 6 months ]

Enrollment: 60
Study Start Date: August 2007
Study Completion Date: August 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug Group
PERIOGEN
Drug: PERIOGEN
Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
Active Comparator: Control group
Beta TCP alone
Drug: Beta TCP alone
Implantation of β-TCP (0.5 g) alone

Detailed Description:
Sixty eligible patients with periodontal defect will randomly receive either beta-TCP implantation (control group) or PERIOGEN implantation, containing beta-TCP and rhPDGF (drug group). The specified primary and secondary end points related to efficacy and safety will be assessed during 6 months study period.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Probing depth ≥7 mm at baseline
  2. Presence of ≥4 mm vertical bone defect with at least 1 bony wall after surgical debridement.
  3. Adequate keratinized tissue to permit complete tissue coverage of defect.
  4. Radiographic base of defect ≥3 mm coronal to the apex of the tooth.

Exclusion Criteria:

  1. Failure to maintain adequate oral hygiene (plaque index>2)
  2. Pregnant and lactating women
  3. History of oral cancer or HIV
  4. Periodontal surgery on treatment-targeted tooth within the last year.
  5. Tooth mobility greater than grade II.
  6. Study tooth exhibiting a class III furacation defect
  7. Localized aggressive periodontitis
  8. Radiographic signs of untreated acute infection at the surgical site
  9. Recent history of smoking more than 20 cigarettes/day
  10. Known allergy to E.coli-derived products
  11. Using an investigational therapy within the past 30 days.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00496847


Locations
India
Sri Sai Dental college of surgery, Vikarabad,
RR Dist, Andhra pradesh, India, 501101
Sponsors and Collaborators
Virchow Group
Investigators
Principal Investigator: A Jayakumar, MDS Sri Sai Dental college of surgery, Vikarabad, RR Dist, AP, India.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Virchow Group
ClinicalTrials.gov Identifier: NCT00496847     History of Changes
Other Study ID Numbers: VB023/07
First Submitted: July 3, 2007
First Posted: July 4, 2007
Last Update Posted: December 16, 2014
Last Verified: November 2009

Keywords provided by Virchow Group:
rhPDGF,
periodontal disease